Humacyte, INC Schedule 13D activist filings

Fresenius Medical Care Holdings, Inc. has established a Rule 10b5-1 trading plan to sell up to 5 million shares of Humacyte, Inc. common stock.

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG have filed an amendment to their Schedule 13D, updating their beneficial ownership of Humacyte, Inc. common stock to 6.8%.

Humacyte, Inc. and Fresenius Medical Care Holdings, Inc. have amended their distribution agreement, granting Humacyte exclusive global rights to distribute Symvess(R) outside the U.S. in exchange for low-single-digit royalties.

Fresenius Medical Care's beneficial ownership in Humacyte, Inc. decreased to 8.4% due to share dilution, not share sales.

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG updated their Schedule 13D filing for Humacyte, Inc., reporting a decreased beneficial ownership percentage due to share dilution and announcing key management changes within Fresenius.

Fresenius Medical Care AG's beneficial ownership in Humacyte, Inc. decreased to 9.9% due to share dilution, while announcing a new CEO for its Care Enablement segment.

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG reported a decrease in their beneficial ownership of Humacyte, Inc. common stock from 14.2% to 11.8%, solely due to an increase in Humacyte's outstanding shares.